9 Meters Biopharma, Inc. (NMTR) Stock Analysis
DELISTED 2023
What happened to 9 Meters Biopharma, Inc. (NMTR) stock?
9 Meters Biopharma, Inc. (NMTR) no longer trades on public markets. It was delisted in July 2023. The figures below are historical and are not a current quote.
- Status:
- Delisted — no longer trades
- Delisting date:
- July 2023
- Last recorded price (historical):
- $0.0722 (last quote on record before the July 2023 delisting; historical, not a current quote)
Market cap $1.04M is the value of all shares combined.
For informational purposes only. Not financial advice. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
9 Meters Biopharma, Inc. (NMTR). 9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare digestive diseases and gastrointestinal conditions. Their pipeline includes Larazotide for celiac disease and Vurolenatide for short bowel syndrome.
Last analyzed: Mar 18, 20269 Meters Biopharma, Inc. (NMTR) Healthcare & Pipeline Overview
More about this archive record
Can I still buy NMTR shares?
No. NMTR stopped trading on public markets in July 2023, so the shares are not available through a broker. Anything you see quoted for NMTR elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before NMTR stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to 9 Meters Biopharma, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.